Analyst Price Targets — ANGO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 4:18 pm | Yi Chen | H.C. Wainwright | $19.00 | $14.49 | TheFly | AngioDynamics price target raised to $19 from $16 at H.C. Wainwright |
| July 15, 2026 10:37 am | — | Canaccord Genuity | $20.00 | $13.00 | TheFly | AngioDynamics price target raised to $20 from $16 at Canaccord |
| October 3, 2025 11:57 am | — | Canaccord Genuity | $18.00 | $11.74 | TheFly | AngioDynamics price target raised to $18 from $17 at Canaccord |
| July 16, 2025 10:57 am | John Young | Canaccord Genuity | $17.00 | $8.72 | TheFly | AngioDynamics price target raised to $17 from $15 at Canaccord |
| October 4, 2024 6:10 am | William Plovanic | Canaccord Genuity | $12.00 | $6.10 | StreetInsider | AngioDynamics (ANGO) PT Lowered to $12 at Canaccord Genuity |
| September 20, 2024 6:50 am | Yi Chen | H.C. Wainwright | $14.00 | $7.70 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on AngioDynamics (ANGO) |
| April 5, 2024 7:15 am | Steven Lichtman | Oppenheimer | $12.00 | $6.40 | TheFly | AngioDynamics upgraded to Outperform from Perform at Oppenheimer |
| January 6, 2023 7:27 am | — | Raymond James | $22.00 | $15.48 | Benzinga | Raymond James Maintains Strong Buy on AngioDynamics, Lowers Price Target to $22 |
| July 13, 2022 7:13 am | — | Raymond James | $27.00 | $20.02 | Benzinga | Raymond James Maintains Strong Buy on AngioDynamics, Lowers Price Target to $27 |
Latest News for ANGO
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANGO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.